QED Therapeutics

Biotechnology, Health Care, Therapeutics
Founded in 2018-01-01
Palo Alto, California, United States
http://qedtx.com
For Profit

About QED Therapeutics

QED Therapeutics, a subsidiary of BridgeBio Pharma, is a biotechnology company focused on precision medicine for FGFR-driven disorders. Their lead candidate is infigratinib, a best-in-class FGFR kinase inhibitor that has shown meaningful clinical activity in chemotherapy-refractory cholangiocarcinoma with FGFR2 fusions. QED is also evaluating infigratinib in preclinical studies for the treatment of achondroplasia. They plan to develop infigratinib in additional FGFR-driven tumor types and rare disorders.

Company Metrics

  • Employees: 1-10
  • Monthly Visits: 190
  • Tech Stack: None active products

Financial Information

  • Estimated Revenue: $1M to $10M
  • Total Funding: 65000000 USD
  • Last Funding: 65000000 USD (Venture - Series Unknown)
  • Funding Status:

Technology Stack

QED Therapeutics actively uses None products in their tech stack.

Market Presence

Industries: Biotechnology, Health Care, Therapeutics

Headquarters: Palo Alto, California, United States